Baricitinib (also known as LY3009104 or INCB028050) is a novel and potent small molecule inhibitor of Janus kinase family of enzymes (JAKs) with selectivity for JAK1 and JAK2. Baricitinib is currently in clinical development for the treatment of rheumatoid arthritis (RA) and other inflammatory disorders.
Contact：Wuhan Sun-shine Bio-technologyCorporation Limited Add: Building C16, No.388 Gaoxin 2Road, East Lake Hi-tech Development Zone, Wuhan 430200, China Tel: +86-27-65522452 QQ：1973737790 Web: http://www.sun-shinechem.com
| 
